Benign Breast Disease Team Project
331
- Marks, Jeffrey — Duke University Medical Center
- Skates, Steven — Massachusetts General Hospital
- Li, Christopher — Fred Hutchinson Cancer Research Center
- Engstrom, Paul — Fox Chase Cancer Center
- Cairns, Paul — Fox Chase Cancer Center
- Stark, Azadeh — Geisinger Health System
- Godwin, Andrew K — University of Kansas Medical Center
- Urban, Nicole — Fred Hutchinson Cancer Research Center
- Feng, Ziding — Fred Hutchinson Cancer Research Center
- Srivastava, Sudhir — National Cancer Institute
A. Paul Cairns (DNA Methylation Sensitivity in IBC)
MAL
RASSF IA
CTGF
HIN1
APC
RAR
GSTP1
IGFBP3
GOS2
B. Andrew Godwin (Protein Biomarker)
C. Indra Poola (Protein Biomarker)
MMP-1
CEA CAM6
HYAL-1
D. Nicole Urban
CAV-1 (Caveolin 1)
FN-1 (fibronectin)
COL1A1
TIMP4
SPP1 (osteopontin)
S100A7 (Psoriasin)
MMP10
MMP12
Other, Specify
Proteomics
Proteomics
Breast and Gynecologic Cancers Research
To identify women diagnosed with atypical ductal hyperplasia (ADH) who are at increased risk of developing invasive breast cancer (IBC) and who might benefit from risk reduction with the use of chemoprevention agents such as Tamoxifen. (Note: A companion protocol will study women with DCIS and their risk for invasive breast cancer.)
Biomarkers expressed in benign breast disease tissue of women who progresse to invasive breast cancer are quantitatively and/or qualitatively different from those expressed in tissue of matched women who do not progress to invasive breast cancer. A nested case-control design will be used to determine if available proteomic and methylation biomarkers predict risk for future invasive cancer (IBC). Women with ADH who are disease-free will be matched 2:1 to women with ADH who progress to IBC.
There are currently no biomarkers annotated for this protocol.
No datasets are currently associated with this protocol.
